©The Author(s) 2026.
World J Hepatol. Feb 27, 2026; 18(2): 114346
Published online Feb 27, 2026. doi: 10.4254/wjh.v18.i2.114346
Published online Feb 27, 2026. doi: 10.4254/wjh.v18.i2.114346
Table 4 Comparison of baseline and endpoint clinical data between tenofovir amibufenamide and entecavir groups in patients with chronic hepatitis B, n (%)/median (interquartile range)/mean ± SD
| Variables | ETV (n = 96) | TMF (n = 48) | ||||
| Baseline | Endpoint | P value | Baseline | Endpoint | P value | |
| DNA positive | 96 (100.00) | 25 (26.04) | < 0.001 | 48 (100.00) | 15 (31.25) | < 0.001 |
| HBsAg (log10IU/mL) | 3.50 (3.07-4.00) | 3.36 (2.97-3.67) | 0.087 | 3.66 (3.07-4.37) | 3.37 (3.02-3.89) | 0.175 |
| HBeAg positive | 46 (47.92) | 38 (39.58) | 0.244 | 21 (43.75) | 20 (41.67) | 0.837 |
| TBIL (μmol/L) | 15.8 (12.1-22.9) | 13.1 (10.1-17.3) | 0.006 | 15.8 (11.9-23.7) | 12.4 (9.5-16.3) | 0.010 |
| Alb (g/L) | 45.6 (43.0-47.5) | 45.44 ± 2.87 | 0.674 | 44.8 (42.4-45.9) | 45.35 ± 2.51 | 0.050 |
| ALT (U/L) | 53.2 (29.0-87.8) | 23.3 (16.8-32.5) | < 0.01 | 45.8 (29.2-74.8) | 26.3 (17.7-42.5) | < 0.01 |
| AST (U/L) | 37.7 (28.2-65.8) | 23.8 (19.3-30.6) | < 0.01 | 35.9 (24.1-57.1) | 22.7 (19.1-32.3) | < 0.01 |
| GGT (U/L) | 27.0 (17.0-53.7) | 21.0 (14.2-28.8) | 0.013 | 31.2 (18.2-59.5) | 23.3 (15.0-35.8) | 0.027 |
| ALP (U/L) | 79.7 (65.7-95.7) | 75.04 ± 20.90 | 0.107 | 86.4 (68.6-101.2) | 82.28 ± 24.97 | 0.575 |
| TG (mmol/L) | 1.07 (0.80-1.62) | 1.14 (0.87-1.45) | 0.481 | 1.24 (0.86-1.75) | 1.38 (0.90-1.91) | 0.354 |
| TC (mmol/L) | 4.43 (3.88-4.86) | 4.39 (3.86-4.91) | 0.977 | 4.53 (4.05-4.76) | 4.62 (4.32-4.91) | 0.096 |
| FBG (mmol/L) | 5.00 (4.68-5.35) | 4.98 (4.63-5.46) | 0.979 | 5.00 (4.76-5.29) | 5.10 (4.77-5.32) | 0.866 |
| SCr (μmol/L) | 66.48 ± 14.14 | 71.17 ± 13.87 | 0.021 | 67.01 ± 11.12 | 67.76 ± 11.36 | 0.745 |
| eGFR (mL/minute/1.73 m2) | 111.83 ± 10.16 | 106.10 ± 12.27 | < 0.001 | 112.50 ± 10.28 | 111.01 ± 10.53 | 0.485 |
| BUN (mmol/L) | 4.18 ± 1.00 | 4.41 ± 1.14 | 0.149 | 4.33 ± 1.11 | 4.64 ± 1.06 | 0.160 |
| HGB (g/L) | 148 (135-159) | 147 (135-158) | 0.947 | 147 (135-159) | 148 (137-158) | 0.840 |
| PLT (× 109/L) | 201 ± 60 | 198 ± 61 | 0.694 | 196 ± 55 | 198 ± 52 | 0.793 |
| LSM (kPa) | 7.2 (6.0-10.3) | 6.8 (5.4-8.5) | 0.150 | 7.0 (6.0-7.6) | 6.8 (5.5-7.8) | 0.322 |
| Liver cirrhosis | 10 (10.42) | 12 (12.50) | 0.650 | 5 (10.42) | 4 (8.33) | 0.726 |
- Citation: Ma SP, Wang L, Zhang YL, Wan X, Liu Q, Tang YL, Malhi LR, Ge SF. Effects of tenofovir amibufenamide and entecavir on estimated glomerular filtration rate in treatment-naïve patients with chronic hepatitis B. World J Hepatol 2026; 18(2): 114346
- URL: https://www.wjgnet.com/1948-5182/full/v18/i2/114346.htm
- DOI: https://dx.doi.org/10.4254/wjh.v18.i2.114346